Minhua Chu, Managing Partner at TransitionValue Partner, shared a post on X:
“Therapeutics’s B7H3 ADC YL201, in combination with Akeso‘s PD-1/VEGF bispecific antibody ivonescimab, has received approval for a clinical trial application for multiple solid tumors.
This marks the first clinical trial combining ivonescimab with an ADC.
Last month, after Akeso‘s first bispecific ADC drug, targeting TROP-2/Nectin-4 (AK146D1), completed its first Phase 1 dosing in Australia, the company introduced the concept of ‘IO+ADC’ 2.0.
YL201 has initiated two Phase 3 clinical trials.”
More posts featuring Minhua Chu.